Emerging therapies for the treatment of nonalcoholic steatohepatitis: A systematic review-Reference-Cited by-同舟云学术

Emerging therapies for the treatment of nonalcoholic steatohepatitis: A systematic review

Published:2021-02-17 Issue:3 Volume:41 Page:315-328
ISSN:0277-0008
Container-title:Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
language:en
Short-container-title:Pharmacotherapy

Author:

Guirguis Erenie¹^ORCID,Grace Yasmin¹,Bolson Anthony¹,DellaVecchia Matthew J.¹,Ruble Melissa²

Affiliation:

1. Lloyd L. Gregory School of Pharmacy Palm Beach Atlantic University West Palm Beach Florida USA

2. Taneja College of Pharmacy University of South Florida Tampa Florida USA

Publisher

Wiley

Subject

Pharmacology (medical)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/phar.2489

Reference83 articles.

1. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

3. NAFLD: A multisystem disease

4. EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease

5. Overview | Non‐alcoholic fatty liver disease (NAFLD): assessment and management | Guidance | NICE.https://www.nice.org.uk/guidance/ng49. Accessed May 15 2020.

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of resmetirom among patients with non-alcoholic steatohepatitis: a systematic review and meta-analysis;Annals of Medicine & Surgery;2024-07-15

2. Upregulation of Hepatic Glutathione S-Transferase Alpha 1 Ameliorates Metabolic Dysfunction-Associated Steatosis by Degrading Fatty Acid Binding Protein 1;International Journal of Molecular Sciences;2024-05-07

3. Advancements in Understanding and Treating NAFLD: A Comprehensive Review of Metabolic-Associated Fatty Liver Disease and Emerging Therapies;Livers;2023-11-07

4. Nonalcoholic liver disease: Epidemiology, risk factors, natural history, and management strategies;Annals of the New York Academy of Sciences;2023-07-03

5. A phase 2, adaptive randomized, double-blind, placebo-controlled, multicenter, 52-week study of HM15211 in patients with biopsy-confirmed non-alcoholic steatohepatitis – Study design and rationale of HM-TRIA-201 study;Contemporary Clinical Trials;2023-07